Montreal cognitive assessment as a cognitive outcome measure in progressive supranuclear palsy.

Bibliographic Details
Title: Montreal cognitive assessment as a cognitive outcome measure in progressive supranuclear palsy.
Authors: Ibrahim, Vanessa, Isroff, Catherine, Stephen, Christopher D., Iyer, Jay, Dale, Marian L., Gunzler, Douglas A., Bayram, Ece, Xie, Tao, Pantelyat, Alex, Montaser-Kouhsari, Leila, Garcia-Cordero, Indira, Tartaglia, Maria Carmela, Lang, Anthony E., Swan, Matthew, Boxer, Adam L., Golbe, Lawrence I., Wills, Anne-Marie
Source: Frontiers in Neurology; 2025, p1-6, 6p
Subject Terms: MONTREAL Cognitive Assessment, PROGRESSIVE supranuclear palsy, NEUROPSYCHOLOGICAL tests, COGNITION disorders, CLINICAL trials
Abstract: Background: The Montreal Cognitive assessment (MoCA) is a well-validated global cognitive screening instrument. Its validity in progressive supranuclear palsy (PSP) has not been assessed. Objectives: To evaluate the MoCA as an outcome measure in PSP clinical trials. Methods: Cognitive data from 162 participants in the placebo arm of the Biogen PASSPORT study (NCT03068468) were analyzed using linear mixed-effects modeling (LMM) and repeated measures correlation. Results: There was a significant decline in the MoCA score over time of −1.4 (95% CI −0.84 to −1.97) points over a 48-week period (p < 0.0001). Small but significant changes (p < 0.01) were observed in all MoCA domains except abstraction. The MoCA correlated weakly with the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) over time (r rm = 0.1, p = 0.02) but exhibited a stronger correlation with the PSP Rating Scale (PSPRS) (r rm = −0.25, p < 0.0001). Conclusion: The MoCA appears to have limited sensitivity in capturing cognitive decline in PSP. [ABSTRACT FROM AUTHOR]
Copyright of Frontiers in Neurology is the property of Frontiers Media S.A. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Complementary Index
More Details
ISSN:16642295
DOI:10.3389/fneur.2024.1501206
Published in:Frontiers in Neurology
Language:English